Category Archives for "News"

Abattis unveils “COMFORT” its proprietary New Chronic Pain and Inflammation Product to Start Shipping November 2018

ABATTIS UNVEILS “COMFORT” ITS PROPRIETARY NEW CHRONIC PAIN AND INFLAMMATION PRODUCT TO START SHIPPING NOVEMBER 2018 September 24, 2018    |    Abattis Bioceuticals Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the pending release of “Comfort”, a nutraceutical designed to target chronic pain and inflammation. As previously announced, the […]

Read More

Abattis Strengthens Management Team and Provides Company Updates

ABATTIS STRENGTHENS MANAGEMENT TEAM AND PROVIDES COMPANY UPDATES September 11, 2018    |    Abattis Bioceuticals Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide the following corporate updates. The Company is pleased to announce the appointment of Nicole Breitinger as the Company’s corporate secretary. Ms. Breitinger brings considerable experience to […]

Read More

ABATTIS PREPARES TO LAUNCH NEW PRODUCTS THROUGH VERGENCE NATURALS

ABATTIS PREPARES TO LAUNCH NEW PRODUCTS THROUGH VERGENCE NATURALS August 28, 2018    |    Abattis Bioceuticals Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it plans to launch a new line of products designed to alleviate pain and inflammation through its wholly owned subsidiary, Vergence Naturals Ltd. (“Vergence”). […]

Read More

ABATTIS COMPLETES SALE OF NORTHERN VINE INTEREST

ABATTIS COMPLETES SALE OF NORTHERN VINE INTEREST August 14, 2018    |    Abattis Bioceuticals Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it has completed the sale (the “Sale”) of its 35% interest in Northern Vine Canada Inc. (“Northern Vine”) to Emerald Health Therapeutics, Inc. (TSXV:EMH / OTCQX:EMHTF) (“Emerald”) […]

Read More

ABATTIS ANNOUNCES SHARE BUY BACK PROGRAM

ABATTIS ANNOUNCES SHARE BUY BACK PROGRAM August 7, 2018    |    Abattis Bioceuticals Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it intends to proceed with a normal course issuer bid to purchase up to 20,986,909 of its common shares, representing 5% of its current issued and outstanding […]

Read More